Popular on TelAve
- Attorney Joseph C. Kreps Files Lawsuit to Stop Alabama State Board of Pharmacy's Unlawful "Revenue-First" Rulemaking - 103
- Advantage Marketing Launches 3-Minute Assessment to Help SMBs Diagnose and Fix Marketing Gaps
- Card makers turn to Pink and Main for tools to support their craft
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- The AAA Metamorphosis: How Global Gaming Is Redefining Production Standards
- GDE Tree Services Expands Operations into Sydney, NSW
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- Understanding Unexpected Death: Why Independent Autopsies Matter in Cases Without Clear Cause
- Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
CCHR Says New OIG Report Raises Concerns about Drugging Elderly with Antipsychotics
TelAve News/10894284
Vulnerable elderly residents face serious risks and premature death from antipsychotics.
LOS ANGELES - TelAve -- By CCHR International
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on TelAve News
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on TelAve News
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
The Citizens Commission on Human Rights International (CCHR), a 57-year mental health industry watchdog, warns that vulnerable elderly residents in some U.S. nursing homes continue to face serious risks of premature death from antipsychotics. Some facilities and their prescribers evade meaningful accountability, and penalties remain too weak to deter the abuse.
The U.S. Department of Health and Human Services Office of Inspector General (OIG) recently issued two reports examining psychotropic drugging in nursing homes. In a review of 40 Centers for Medicare and Medicaid Services (CMS) inspections, the OIG found that some facilities routinely administered antipsychotics—drugs not Food and Drug Administration (FDA)-approved for dementia and linked to increased mortality—to control resident behavior, while frequently failing to implement required safeguards.[1]
"The inappropriate use of antipsychotic drugs in nursing homes has been a longstanding concern for Congress and others," the OIG stated. The reports also addressed how some nursing homes misdiagnose residents with "schizophrenia" to bypass accountability and artificially improve public quality ratings. The OIG recommended that CMS strengthen oversight, closely monitor schizophrenia diagnosis rates, target high-risk facilities, and ensure residents and families receive clear information about antipsychotic use.
CCHR's international president, Jan Eastgate, responded: "For decades, this abuse has been reported, with promises of increased oversight. These latest government reports reinforce that our elderly are being misdiagnosed and plied with debilitating antipsychotics." Current penalties—capped at $1,000–$5,000 for false certifications—are inadequate, she said.
More on TelAve News
- Xtel Communications Appoints David Appleman as VP of Strategic Sales
- L2 Aviation Acquires Advance Aero
- $112 Million Contract Backlog for Cycurion (N A S D A Q: CYCU) Enters Hyper-Growth Phase With, Strategic Acquisitions, & Exploding AI Cybersecurity
- HarryPotterObamaSonic10Inu Celebrates World Record 1,000+ Days Livestream with Record-Breaking Merchandise Launch
- Igniting High-Growth Expansion as Electrification Strategy and Infrastructure Dominance Converge; 88% Revenue Growth (N Y S E: MWG)
In 2011, OIG Inspector General Daniel Levinson declared: "Government, taxpayers, nursing home residents, as well as their families and caregivers, should be outraged—and seek solutions."[2] In 2023, HHS had identified serious problems with inappropriate antipsychotic use and inaccurate schizophrenia diagnoses, but the agency did not impose substantial financial penalties at the time.[2]
Antipsychotics carry well-documented dangers for the elderly. In 2005, the Food and Drug Administration (FDA) issued a black-box warning for their use in dementia patients due to elevated death risks.[3] In 2007, FDA senior drug safety official Dr. David Graham warned that at least 15,000 nursing home residents die annually from these drugs.[4] A 2024 American Association of Retired Persons report found that in people with dementia aged 50 and older, antipsychotics more than doubled the risk of pneumonia—the leading cause of death in this population—while also increasing risks of stroke, acute kidney injury, blood clots, bone fractures, heart attack, and heart failure.[5]
The problem dates back decades:
1987: Congress passed the Omnibus Reconciliation Act, including the Nursing Home Reform Act, intended to curb chemical restraints; the practice shifted to medication-based "chemical restraints."[6]
2007: Sen. Chuck Grassley called for an OIG review of antipsychotic use and marketing in nursing homes.[7]
2012–2015: CMS's National Partnership to Improve Dementia Care reduced prescribing somewhat, but schizophrenia diagnoses rose sharply, undermining progress.[8]
2019–2020: Roughly 20% of skilled nursing facility residents—about 298,650 people weekly—received antipsychotics. A House Ways and Means report described the crisis as "one of patient harm, inadequate oversight, and insufficient staffing."[9]
More on TelAve News
- Appliance EMT Presents Multi-Thousand Dollar Donation to Kids Motel Ministry to Support Local Families
- New Report Reveals Plane Crashes Are Not Where You'd Think
- Whiteside & Goldberg Investigating Claims on Behalf of Victims in TJ Maxx Hidden Camera Incident in Machesney Park, Illinois
- "Fearless and Free": Long Beach Pride 2026 Celebrates Resilience, Family, and Multicultural Connection
- 50 Years of Small Business Wisdom, Supercharged by AI: Shelly Berman Launches The Business Health Check
Eastgate concluded, "This continued drugging despite repeated investigations needs to change. Accountability is vital because our seniors deserve compassion and safety, not sedation and premature death."
CCHR urges Congress, CMS, and state authorities to enact immediate, enforceable protections—including strong penalties on any prescribers and facilities engaged in such practices—and to prioritize non-drug alternatives for behavioral care in nursing homes.
CCHR is a nonprofit mental health watchdog, established by the Church of Scientology and Professor of Psychiatry, Thomas Szasz, M.D., dedicated to eradicating abuses committed under the guise of mental health care. Since 1969, CCHR has helped secure hundreds of laws protecting individuals from coercive psychiatric practices.
Sources:
[1] Nursing Homes' Inappropriate Use of Antipsychotic Drugs Poses a Risk to Residents, OIG, 16 Mar. 2026, oig.hhs.gov/reports/all/2026/nursing-homes-inappropriate-use-of-antipsychotic-drugs-poses-a-risk-to-residents/
[2] "Overmedication of Nursing Home Patients Troubling," OIG, 1 June 2011
[3] "Nursing Homes Under Investigation for Abuse of Antipsychotics," Newsmax.com, 18 Jan. 2023
[4] Jeanne Lenzer, "FDA warns about using antipsychotic drugs for dementia," BMJ, 23 Apr. 2005,
[5] Testimony by Dr. David Graham, House Hearing, 110th Congress – The Adequacy of FDA to Assure the Safety of the Nation's Drug Supply General, 13 Feb. 2007, p. 66
[6] "Antipsychotics Pose New Risks for People With Dementia," AARP, 24 Apr. 2024, Updated 27 Jan. 2026
[7] P S Masand, "Side effects of antipsychotics in the elderly "J Clin Psychiatry, 2000
[8] "Under-Enforced and Over-Prescribed: The Antipsychotic Drug Epidemic Ravaging America's Nursing Homes." Report of the Committee on Ways and Means Majority U.S. House of Representatives, July 2020, p. 9
[9] "Long-Term Trends of Psychotropic Drug Use in Nursing Homes," Health and Human Services Office of the Inspector General, 11 Nov. 2022
Source: Citizens Commission on Human Rights International
0 Comments
Latest on TelAve News
- UK AltNet FullFibre Solves IPv4 Shortage With netElastic BNG And CGNAT Networking Software
- Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada
- Seven Games That Make You Think (and Smile) Earn 2026 Mensa Select® Honors
- New Research Reveals Gen Z Trusts Independent Sources Over Influencers — Exposing What We are Talker Calls "The Independent Validation Gap"
- New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away
- PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
- Ailias Launches Global Partner Programme for AI-Powered Conversational Digital Humans in Events and Experiences
- Village People Headline "Rock The Rainbow" Phuket Pride Finale 2026
- SilverBow Strategies Launches RFPArchon™, the First Product in Its Artemis AI Solutions™ Suite
- Sawasdee Anime Launches Animenture: A Gamified SNS Connecting Global Fans to 2,000+ Anime Sites
- "LOOK UP CAFE TOKYO SKYTREE" to Open on May 22, 2026 on the 5th floor of TOKYO SKYTREE®. This Date also Marks TOKYO SKYTREE's 14th Anniversary
- "Rehabilitative Prison Program Compromised by Alleged Staff Misconduct, Whistleblower Claims"
- Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
- The Hardest Part of Building an App Isn't Starting - It's Finishing
- Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
- Colorfront Launches New Mac App For Creating Apple Immersive Video
- Michele Mundy's "Divinely Tailored" Gains Momentum
- Evermore Bliss Launches AI Wedding Speech Writer to Help Users Create Personalized, Heartfelt Toasts
- Keenethics enters the ChatGPT Apps ecosystem as a new growth opportunity for businesses
- Spring Into Your New Home at Heritage at South Brunswick
